piracetam has been researched along with Chronic Kidney Failure in 6 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Noncompartmental pharmacokinetic parameters were calculated and steady-state profiles were simulated using the superposition method." | 2.79 | Levetiracetam pharmacokinetics in Japanese subjects with renal impairment. ( Kumagai, Y; Stockis, A; Toublanc, N; Yamamoto, J, 2014) |
| " Heparin dosage was not reduced during HD using QB 200 ml, QD 500 ml, and no ultrafiltration." | 2.66 | A pilot study of piracetam in cuprophan hemodialysis. ( Alivanis, P; Grekas, D; Karamouzis, M; Pyrpasopoulos, M; Tourkantonis, A, 1989) |
| " The results of these studies indicate that higher doses need to be used for children (on a per-weight basis), and individuals with renal dysfunction require dosage modifications related to creatinine clearance." | 2.41 | Use of levetiracetam in special populations. ( French, J, 2001) |
| " In end-stage renal disease (ESRD) patients on hemodialysis (HD), pharmacokinetic studies recommend daily dosing with 50% supplemental doses after 4-hour HD sessions." | 1.46 | Comparison of Levetiracetam Dosing Regimens in End-Stage Renal Disease Patients Undergoing Intermittent Hemodialysis. ( Sands, KA; Shiue, HJ; Taylor, M, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shiue, HJ | 1 |
| Taylor, M | 1 |
| Sands, KA | 1 |
| Yamamoto, J | 1 |
| Toublanc, N | 1 |
| Kumagai, Y | 1 |
| Stockis, A | 1 |
| French, J | 1 |
| Schaefer, RM | 1 |
| Seufert, H | 1 |
| Schafferhans, K | 1 |
| Gilge, U | 1 |
| Schulz, HU | 1 |
| Pooth, R | 1 |
| Heidland, A | 1 |
| Grekas, D | 2 |
| Alivanis, P | 2 |
| Karamouzis, M | 2 |
| Pyrpasopoulos, M | 2 |
| Tourkantonis, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Study of Pharmacokinetics of Levetiracetam in Patients Undergoing Intermittent Hemodialysis[NCT04511676] | 12 participants (Actual) | Observational | 2018-11-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for piracetam and Chronic Kidney Failure
| Article | Year |
|---|---|
Use of levetiracetam in special populations.
Topics: Adult; Age Factors; Aged; Anticonvulsants; Child; Comorbidity; Contraceptives, Oral; Drug Approval; | 2001 |
2 trials available for piracetam and Chronic Kidney Failure
| Article | Year |
|---|---|
Levetiracetam pharmacokinetics in Japanese subjects with renal impairment.
Topics: Adult; Aged; Animals; Case-Control Studies; Dose-Response Relationship, Drug; Humans; Japan; Kidney | 2014 |
A pilot study of piracetam in cuprophan hemodialysis.
Topics: Adult; Aged; Biocompatible Materials; Cellulose; Female; Humans; Kidney Failure, Chronic; Male; Memb | 1989 |
3 other studies available for piracetam and Chronic Kidney Failure
| Article | Year |
|---|---|
Comparison of Levetiracetam Dosing Regimens in End-Stage Renal Disease Patients Undergoing Intermittent Hemodialysis.
Topics: Adult; Aged; Anticonvulsants; Clinical Protocols; Drug Administration Schedule; Female; Humans; Kidn | 2017 |
[Determination of glomerular filtration rate in man using single shot piracetam clearance].
Topics: Creatinine; Glomerular Filtration Rate; Humans; Infusions, Intravenous; Inulin; Kidney Failure, Chro | 1992 |
Piracetam as a potent inhibitor of plasma thromboxane B2 during hemodialysis.
Topics: Adult; Aged; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Piracetam; Pyrrolidinones; | 1989 |